Global Pancreatic Endocrine Tumor Drug Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

  • receipt Report ID : 118870
  • calendar_today Published On: Mar, 2022
  • file_copy Pages: 156
  • list Pharmaceuticals and Healthcare
Buy @ $3500

The Pancreatic Endocrine Tumor Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest study, due to COVID-19 pandemic, the global Pancreatic Endocrine Tumor Drug market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Clinic accounting for % of the Pancreatic Endocrine Tumor Drug global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Buparlisib Hydrochloride segment is altered to a % CAGR between 2022 and 2028.

Global key manufacturers of Pancreatic Endocrine Tumor Drug include Ipsen S.A., Jiangsu Hengrui Medicine Co., Ltd., MediaPharma s.r.l., Novartis AG, and OXiGENE, Inc., etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation

Pancreatic Endocrine Tumor Drug market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

Buparlisib Hydrochloride

Dovitinib Lactate

Fosbretabulin Tromethamine

Lanreotide Acetate

MPHE-001B

Others

Market segment by Application can be divided into

Clinic

Research Center

Hospital

The key market players for global Pancreatic Endocrine Tumor Drug market are listed below:

Ipsen S.A.

Jiangsu Hengrui Medicine Co., Ltd.

MediaPharma s.r.l.

Novartis AG

OXiGENE, Inc.

Market segment by region, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Pancreatic Endocrine Tumor Drug product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Pancreatic Endocrine Tumor Drug, with price, sales, revenue and global market share of Pancreatic Endocrine Tumor Drug from 2019 to 2022.

Chapter 3, the Pancreatic Endocrine Tumor Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Pancreatic Endocrine Tumor Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Pancreatic Endocrine Tumor Drug market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of Pancreatic Endocrine Tumor Drug.

Chapter 13, 14, and 15, to describe Pancreatic Endocrine Tumor Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Pancreatic Endocrine Tumor Drug Introduction

1.2 Market Analysis by Type

1.2.1 Overview: Global Pancreatic Endocrine Tumor Drug Revenue by Type: 2017 Versus 2021 Versus 2028

1.2.2 Buparlisib Hydrochloride

1.2.3 Dovitinib Lactate

1.2.4 Fosbretabulin Tromethamine

1.2.5 Lanreotide Acetate

1.2.6 MPHE-001B

1.2.7 Others

1.3 Market Analysis by Application

1.3.1 Overview: Global Pancreatic Endocrine Tumor Drug Revenue by Application: 2017 Versus 2021 Versus 2028

1.3.2 Clinic

1.3.3 Research Center

1.3.4 Hospital

1.4 Global Pancreatic Endocrine Tumor Drug Market Size & Forecast

1.4.1 Global Pancreatic Endocrine Tumor Drug Sales in Value (2017 & 2021 & 2028)

1.4.2 Global Pancreatic Endocrine Tumor Drug Sales in Volume (2017-2028)

1.4.3 Global Pancreatic Endocrine Tumor Drug Price (2017-2028)

1.5 Global Pancreatic Endocrine Tumor Drug Production Capacity Analysis

1.5.1 Global Pancreatic Endocrine Tumor Drug Total Production Capacity (2017-2028)

1.5.2 Global Pancreatic Endocrine Tumor Drug Production Capacity by Geographic Region

1.6 Market Drivers, Restraints and Trends

1.6.1 Pancreatic Endocrine Tumor Drug Market Drivers

1.6.2 Pancreatic Endocrine Tumor Drug Market Restraints

1.6.3 Pancreatic Endocrine Tumor Drug Trends Analysis

2 Manufacturers Profiles

2.1 Ipsen S.A.

2.1.1 Ipsen S.A. Details

2.1.2 Ipsen S.A. Major Business

2.1.3 Ipsen S.A. Pancreatic Endocrine Tumor Drug Product and Services

2.1.4 Ipsen S.A. Pancreatic Endocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2 Jiangsu Hengrui Medicine Co., Ltd.

2.2.1 Jiangsu Hengrui Medicine Co., Ltd. Details

2.2.2 Jiangsu Hengrui Medicine Co., Ltd. Major Business

2.2.3 Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Product and Services

2.2.4 Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3 MediaPharma s.r.l.

2.3.1 MediaPharma s.r.l. Details

2.3.2 MediaPharma s.r.l. Major Business

2.3.3 MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Product and Services

2.3.4 MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4 Novartis AG

2.4.1 Novartis AG Details

2.4.2 Novartis AG Major Business

2.4.3 Novartis AG Pancreatic Endocrine Tumor Drug Product and Services

2.4.4 Novartis AG Pancreatic Endocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5 OXiGENE, Inc.

2.5.1 OXiGENE, Inc. Details

2.5.2 OXiGENE, Inc. Major Business

2.5.3 OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Product and Services

2.5.4 OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

3 Pancreatic Endocrine Tumor Drug Breakdown Data by Manufacturer

3.1 Global Pancreatic Endocrine Tumor Drug Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)

3.2 Global Pancreatic Endocrine Tumor Drug Revenue by Manufacturer (2019, 2020, 2021, and 2022)

3.3 Key Manufacturer Market Position in Pancreatic Endocrine Tumor Drug

3.4 Market Concentration Rate

3.4.1 Top 3 Pancreatic Endocrine Tumor Drug Manufacturer Market Share in 2021

3.4.2 Top 6 Pancreatic Endocrine Tumor Drug Manufacturer Market Share in 2021

3.5 Global Pancreatic Endocrine Tumor Drug Production Capacity by Company: 2021 VS 2022

3.6 Manufacturer by Geography: Head Office and Pancreatic Endocrine Tumor Drug Production Site

3.7 New Entrant and Capacity Expansion Plans

3.8 Mergers & Acquisitions

4 Market Analysis by Region

4.1 Global Pancreatic Endocrine Tumor Drug Market Size by Region

4.1.1 Global Pancreatic Endocrine Tumor Drug Sales in Volume by Region (2017-2028)

4.1.2 Global Pancreatic Endocrine Tumor Drug Revenue by Region (2017-2028)

4.2 North America Pancreatic Endocrine Tumor Drug Revenue (2017-2028)

4.3 Europe Pancreatic Endocrine Tumor Drug Revenue (2017-2028)

4.4 Asia-Pacific Pancreatic Endocrine Tumor Drug Revenue (2017-2028)

4.5 South America Pancreatic Endocrine Tumor Drug Revenue (2017-2028)

4.6 Middle East and Africa Pancreatic Endocrine Tumor Drug Revenue (2017-2028)

5 Market Segment by Type

5.1 Global Pancreatic Endocrine Tumor Drug Sales in Volume by Type (2017-2028)

5.2 Global Pancreatic Endocrine Tumor Drug Revenue by Type (2017-2028)

5.3 Global Pancreatic Endocrine Tumor Drug Price by Type (2017-2028)

6 Market Segment by Application

6.1 Global Pancreatic Endocrine Tumor Drug Sales in Volume by Application (2017-2028)

6.2 Global Pancreatic Endocrine Tumor Drug Revenue by Application (2017-2028)

6.3 Global Pancreatic Endocrine Tumor Drug Price by Application (2017-2028)

7 North America by Country, by Type, and by Application

7.1 North America Pancreatic Endocrine Tumor Drug Sales by Type (2017-2028)

7.2 North America Pancreatic Endocrine Tumor Drug Sales by Application (2017-2028)

7.3 North America Pancreatic Endocrine Tumor Drug Market Size by Country

7.3.1 North America Pancreatic Endocrine Tumor Drug Sales in Volume by Country (2017-2028)

7.3.2 North America Pancreatic Endocrine Tumor Drug Revenue by Country (2017-2028)

7.3.3 United States Market Size and Forecast (2017-2028)

7.3.4 Canada Market Size and Forecast (2017-2028)

7.3.5 Mexico Market Size and Forecast (2017-2028)

8 Europe by Country, by Type, and by Application

8.1 Europe Pancreatic Endocrine Tumor Drug Sales by Type (2017-2028)

8.2 Europe Pancreatic Endocrine Tumor Drug Sales by Application (2017-2028)

8.3 Europe Pancreatic Endocrine Tumor Drug Market Size by Country

8.3.1 Europe Pancreatic Endocrine Tumor Drug Sales in Volume by Country (2017-2028)

8.3.2 Europe Pancreatic Endocrine Tumor Drug Revenue by Country (2017-2028)

8.3.3 Germany Market Size and Forecast (2017-2028)

8.3.4 France Market Size and Forecast (2017-2028)

8.3.5 United Kingdom Market Size and Forecast (2017-2028)

8.3.6 Russia Market Size and Forecast (2017-2028)

8.3.7 Italy Market Size and Forecast (2017-2028)

9 Asia-Pacific by Region, by Type, and by Application

9.1 Asia-Pacific Pancreatic Endocrine Tumor Drug Sales by Type (2017-2028)

9.2 Asia-Pacific Pancreatic Endocrine Tumor Drug Sales by Application (2017-2028)

9.3 Asia-Pacific Pancreatic Endocrine Tumor Drug Market Size by Region

9.3.1 Asia-Pacific Pancreatic Endocrine Tumor Drug Sales in Volume by Region (2017-2028)

9.3.2 Asia-Pacific Pancreatic Endocrine Tumor Drug Revenue by Region (2017-2028)

9.3.3 China Market Size and Forecast (2017-2028)

9.3.4 Japan Market Size and Forecast (2017-2028)

9.3.5 Korea Market Size and Forecast (2017-2028)

9.3.6 India Market Size and Forecast (2017-2028)

9.3.7 Southeast Asia Market Size and Forecast (2017-2028)

9.3.8 Australia Market Size and Forecast (2017-2028)

10 South America by Region, by Type, and by Application

10.1 South America Pancreatic Endocrine Tumor Drug Sales by Type (2017-2028)

10.2 South America Pancreatic Endocrine Tumor Drug Sales by Application (2017-2028)

10.3 South America Pancreatic Endocrine Tumor Drug Market Size by Country

10.3.1 South America Pancreatic Endocrine Tumor Drug Sales in Volume by Country (2017-2028)

10.3.2 South America Pancreatic Endocrine Tumor Drug Revenue by Country (2017-2028)

10.3.3 Brazil Market Size and Forecast (2017-2028)

10.3.4 Argentina Market Size and Forecast (2017-2028)

11 Middle East & Africa by Country, by Type, and by Application

11.1 Middle East & Africa Pancreatic Endocrine Tumor Drug Sales by Type (2017-2028)

11.2 Middle East & Africa Pancreatic Endocrine Tumor Drug Sales by Application (2017-2028)

11.3 Middle East & Africa Pancreatic Endocrine Tumor Drug Market Size by Country

11.3.1 Middle East & Africa Pancreatic Endocrine Tumor Drug Sales in Volume by Country (2017-2028)

11.3.2 Middle East & Africa Pancreatic Endocrine Tumor Drug Revenue by Country (2017-2028)

11.3.3 Turkey Market Size and Forecast (2017-2028)

11.3.4 Egypt Market Size and Forecast (2017-2028)

11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)

11.3.6 South Africa Market Size and Forecast (2017-2028)

12 Raw Material and Industry Chain

12.1 Raw Material of Pancreatic Endocrine Tumor Drug and Key Manufacturers

12.2 Manufacturing Costs Percentage of Pancreatic Endocrine Tumor Drug

12.3 Pancreatic Endocrine Tumor Drug Production Process

12.4 Pancreatic Endocrine Tumor Drug Industrial Chain

13 Sales Channel, Distributors, Traders and Dealers

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.2 Pancreatic Endocrine Tumor Drug Typical Distributors

13.3 Pancreatic Endocrine Tumor Drug Typical Customers

14 Research Findings and Conclusion

15 Appendix

15.1 Methodology

15.2 Research Process and Data Source

15.3 Disclaimer

List of Tables

Table 1. Global Pancreatic Endocrine Tumor Drug Revenue by Type, (USD Million), 2017 & 2021 & 2028

Table 2. Global Pancreatic Endocrine Tumor Drug Revenue by Application, (USD Million), 2017 & 2021 & 2028

Table 3. Ipsen S.A. Basic Information, Manufacturing Base and Competitors

Table 4. Ipsen S.A. Major Business

Table 5. Ipsen S.A. Pancreatic Endocrine Tumor Drug Product and Services

Table 6. Ipsen S.A. Pancreatic Endocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 7. Jiangsu Hengrui Medicine Co., Ltd. Basic Information, Manufacturing Base and Competitors

Table 8. Jiangsu Hengrui Medicine Co., Ltd. Major Business

Table 9. Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Product and Services

Table 10. Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 11. MediaPharma s.r.l. Basic Information, Manufacturing Base and Competitors

Table 12. MediaPharma s.r.l. Major Business

Table 13. MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Product and Services

Table 14. MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 15. Novartis AG Basic Information, Manufacturing Base and Competitors

Table 16. Novartis AG Major Business

Table 17. Novartis AG Pancreatic Endocrine Tumor Drug Product and Services

Table 18. Novartis AG Pancreatic Endocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 19. OXiGENE, Inc. Basic Information, Manufacturing Base and Competitors

Table 20. OXiGENE, Inc. Major Business

Table 21. OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Product and Services

Table 22. OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 23. Global Pancreatic Endocrine Tumor Drug Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Pcs)

Table 24. Global Pancreatic Endocrine Tumor Drug Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)

Table 25. Market Position of Manufacturers in Pancreatic Endocrine Tumor Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021

Table 26. Global Pancreatic Endocrine Tumor Drug Production Capacity by Company, (K Pcs): 2020 VS 2021

Table 27. Head Office and Pancreatic Endocrine Tumor Drug Production Site of Key Manufacturer

Table 28. Pancreatic Endocrine Tumor Drug New Entrant and Capacity Expansion Plans

Table 29. Pancreatic Endocrine Tumor Drug Mergers & Acquisitions in the Past Five Years

Table 30. Global Pancreatic Endocrine Tumor Drug Sales by Region (2017-2022) & (K Pcs)

Table 31. Global Pancreatic Endocrine Tumor Drug Sales by Region (2023-2028) & (K Pcs)

Table 32. Global Pancreatic Endocrine Tumor Drug Revenue by Region (2017-2022) & (USD Million)

Table 33. Global Pancreatic Endocrine Tumor Drug Revenue by Region (2023-2028) & (USD Million)

Table 34. Global Pancreatic Endocrine Tumor Drug Sales by Type (2017-2022) & (K Pcs)

Table 35. Global Pancreatic Endocrine Tumor Drug Sales by Type (2023-2028) & (K Pcs)

Table 36. Global Pancreatic Endocrine Tumor Drug Revenue by Type (2017-2022) & (USD Million)

Table 37. Global Pancreatic Endocrine Tumor Drug Revenue by Type (2023-2028) & (USD Million)

Table 38. Global Pancreatic Endocrine Tumor Drug Price by Type (2017-2022) & (USD/Pcs)

Table 39. Global Pancreatic Endocrine Tumor Drug Price by Type (2023-2028) & (USD/Pcs)

Table 40. Global Pancreatic Endocrine Tumor Drug Sales by Application (2017-2022) & (K Pcs)

Table 41. Global Pancreatic Endocrine Tumor Drug Sales by Application (2023-2028) & (K Pcs)

Table 42. Global Pancreatic Endocrine Tumor Drug Revenue by Application (2017-2022) & (USD Million)

Table 43. Global Pancreatic Endocrine Tumor Drug Revenue by Application (2023-2028) & (USD Million)

Table 44. Global Pancreatic Endocrine Tumor Drug Price by Application (2017-2022) & (USD/Pcs)

Table 45. Global Pancreatic Endocrine Tumor Drug Price by Application (2023-2028) & (USD/Pcs)

Table 46. North America Pancreatic Endocrine Tumor Drug Sales by Country (2017-2022) & (K Pcs)

Table 47. North America Pancreatic Endocrine Tumor Drug Sales by Country (2023-2028) & (K Pcs)

Table 48. North America Pancreatic Endocrine Tumor Drug Revenue by Country (2017-2022) & (USD Million)

Table 49. North America Pancreatic Endocrine Tumor Drug Revenue by Country (2023-2028) & (USD Million)

Table 50. North America Pancreatic Endocrine Tumor Drug Sales by Type (2017-2022) & (K Pcs)

Table 51. North America Pancreatic Endocrine Tumor Drug Sales by Type (2023-2028) & (K Pcs)

Table 52. North America Pancreatic Endocrine Tumor Drug Sales by Application (2017-2022) & (K Pcs)

Table 53. North America Pancreatic Endocrine Tumor Drug Sales by Application (2023-2028) & (K Pcs)

Table 54. Europe Pancreatic Endocrine Tumor Drug Sales by Country (2017-2022) & (K Pcs)

Table 55. Europe Pancreatic Endocrine Tumor Drug Sales by Country (2023-2028) & (K Pcs)

Table 56. Europe Pancreatic Endocrine Tumor Drug Revenue by Country (2017-2022) & (USD Million)

Table 57. Europe Pancreatic Endocrine Tumor Drug Revenue by Country (2023-2028) & (USD Million)

Table 58. Europe Pancreatic Endocrine Tumor Drug Sales by Type (2017-2022) & (K Pcs)

Table 59. Europe Pancreatic Endocrine Tumor Drug Sales by Type (2023-2028) & (K Pcs)

Table 60. Europe Pancreatic Endocrine Tumor Drug Sales by Application (2017-2022) & (K Pcs)

Table 61. Europe Pancreatic Endocrine Tumor Drug Sales by Application (2023-2028) & (K Pcs)

Table 62. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales by Region (2017-2022) & (K Pcs)

Table 63. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales by Region (2023-2028) & (K Pcs)

Table 64. Asia-Pacific Pancreatic Endocrine Tumor Drug Revenue by Region (2017-2022) & (USD Million)

Table 65. Asia-Pacific Pancreatic Endocrine Tumor Drug Revenue by Region (2023-2028) & (USD Million)

Table 66. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales by Type (2017-2022) & (K Pcs)

Table 67. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales by Type (2023-2028) & (K Pcs)

Table 68. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales by Application (2017-2022) & (K Pcs)

Table 69. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales by Application (2023-2028) & (K Pcs)

Table 70. South America Pancreatic Endocrine Tumor Drug Sales by Country (2017-2022) & (K Pcs)

Table 71. South America Pancreatic Endocrine Tumor Drug Sales by Country (2023-2028) & (K Pcs)

Table 72. South America Pancreatic Endocrine Tumor Drug Revenue by Country (2017-2022) & (USD Million)

Table 73. South America Pancreatic Endocrine Tumor Drug Revenue by Country (2023-2028) & (USD Million)

Table 74. South America Pancreatic Endocrine Tumor Drug Sales by Type (2017-2022) & (K Pcs)

Table 75. South America Pancreatic Endocrine Tumor Drug Sales by Type (2023-2028) & (K Pcs)

Table 76. South America Pancreatic Endocrine Tumor Drug Sales by Application (2017-2022) & (K Pcs)

Table 77. South America Pancreatic Endocrine Tumor Drug Sales by Application (2023-2028) & (K Pcs)

Table 78. Middle East & Africa Pancreatic Endocrine Tumor Drug Sales by Region (2017-2022) & (K Pcs)

Table 79. Middle East & Africa Pancreatic Endocrine Tumor Drug Sales by Region (2023-2028) & (K Pcs)

Table 80. Middle East & Africa Pancreatic Endocrine Tumor Drug Revenue by Region (2017-2022) & (USD Million)

Table 81. Middle East & Africa Pancreatic Endocrine Tumor Drug Revenue by Region (2023-2028) & (USD Million)

Table 82. Middle East & Africa Pancreatic Endocrine Tumor Drug Sales by Type (2017-2022) & (K Pcs)

Table 83. Middle East & Africa Pancreatic Endocrine Tumor Drug Sales by Type (2023-2028) & (K Pcs)

Table 84. Middle East & Africa Pancreatic Endocrine Tumor Drug Sales by Application (2017-2022) & (K Pcs)

Table 85. Middle East & Africa Pancreatic Endocrine Tumor Drug Sales by Application (2023-2028) & (K Pcs)

Table 86. Pancreatic Endocrine Tumor Drug Raw Material

Table 87. Key Manufacturers of Pancreatic Endocrine Tumor Drug Raw Materials

Table 88. Direct Channel Pros & Cons

Table 89. Indirect Channel Pros & Cons

Table 90. Pancreatic Endocrine Tumor Drug Typical Distributors

Table 91. Pancreatic Endocrine Tumor Drug Typical Customers

List of Figures

Figure 1. Pancreatic Endocrine Tumor Drug Picture

Figure 2. Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Type in 2021

Figure 3. Buparlisib Hydrochloride

Figure 4. Dovitinib Lactate

Figure 5. Fosbretabulin Tromethamine

Figure 6. Lanreotide Acetate

Figure 7. MPHE-001B

Figure 8. Others

Figure 9. Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Application in 2021

Figure 10. Clinic

Figure 11. Research Center

Figure 12. Hospital

Figure 13. Global Pancreatic Endocrine Tumor Drug Revenue, (USD Million) & (K Pcs): 2017 & 2021 & 2028

Figure 14. Global Pancreatic Endocrine Tumor Drug Revenue and Forecast (2017-2028) & (USD Million)

Figure 15. Global Pancreatic Endocrine Tumor Drug Sales (2017-2028) & (K Pcs)

Figure 16. Global Pancreatic Endocrine Tumor Drug Price (2017-2028) & (USD/Pcs)

Figure 17. Global Pancreatic Endocrine Tumor Drug Production Capacity (2017-2028) & (K Pcs)

Figure 18. Global Pancreatic Endocrine Tumor Drug Production Capacity by Geographic Region: 2022 VS 2028

Figure 19. Pancreatic Endocrine Tumor Drug Market Drivers

Figure 20. Pancreatic Endocrine Tumor Drug Market Restraints

Figure 21. Pancreatic Endocrine Tumor Drug Market Trends

Figure 22. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Manufacturer in 2021

Figure 23. Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Manufacturer in 2021

Figure 24. Pancreatic Endocrine Tumor Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021

Figure 25. Top 3 Pancreatic Endocrine Tumor Drug Manufacturer (Revenue) Market Share in 2021

Figure 26. Top 6 Pancreatic Endocrine Tumor Drug Manufacturer (Revenue) Market Share in 2021

Figure 27. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Region (2017-2028)

Figure 28. Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Region (2017-2028)

Figure 29. North America Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (USD Million)

Figure 30. Europe Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (USD Million)

Figure 31. Asia-Pacific Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (USD Million)

Figure 32. South America Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (USD Million)

Figure 33. Middle East & Africa Pancreatic Endocrine Tumor Drug Revenue (2017-2028) & (USD Million)

Figure 34. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Type (2017-2028)

Figure 35. Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Type (2017-2028)

Figure 36. Global Pancreatic Endocrine Tumor Drug Price by Type (2017-2028) & (USD/Pcs)

Figure 37. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Application (2017-2028)

Figure 38. Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Application (2017-2028)

Figure 39. Global Pancreatic Endocrine Tumor Drug Price by Application (2017-2028) & (USD/Pcs)

Figure 40. North America Pancreatic Endocrine Tumor Drug Sales Market Share by Type (2017-2028)

Figure 41. North America Pancreatic Endocrine Tumor Drug Sales Market Share by Application (2017-2028)

Figure 42. North America Pancreatic Endocrine Tumor Drug Sales Market Share by Country (2017-2028)

Figure 43. North America Pancreatic Endocrine Tumor Drug Revenue Market Share by Country (2017-2028)

Figure 44. United States Pancreatic Endocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 45. Canada Pancreatic Endocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 46. Mexico Pancreatic Endocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 47. Europe Pancreatic Endocrine Tumor Drug Sales Market Share by Type (2017-2028)

Figure 48. Europe Pancreatic Endocrine Tumor Drug Sales Market Share by Application (2017-2028)

Figure 49. Europe Pancreatic Endocrine Tumor Drug Sales Market Share by Country (2017-2028)

Figure 50. Europe Pancreatic Endocrine Tumor Drug Revenue Market Share by Country (2017-2028)

Figure 51. Germany Pancreatic Endocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 52. France Pancreatic Endocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 53. United Kingdom Pancreatic Endocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 54. Russia Pancreatic Endocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 55. Italy Pancreatic Endocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 56. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales Market Share by Region (2017-2028)

Figure 57. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales Market Share by Application (2017-2028)

Figure 58. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales Market Share by Region (2017-2028)

Figure 59. Asia-Pacific Pancreatic Endocrine Tumor Drug Revenue Market Share by Region (2017-2028)

Figure 60. China Pancreatic Endocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 61. Japan Pancreatic Endocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 62. Korea Pancreatic Endocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 63. India Pancreatic Endocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 64. Southeast Asia Pancreatic Endocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 65. Australia Pancreatic Endocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 66. South America Pancreatic Endocrine Tumor Drug Sales Market Share by Type (2017-2028)

Figure 67. South America Pancreatic Endocrine Tumor Drug Sales Market Share by Application (2017-2028)

Figure 68. South America Pancreatic Endocrine Tumor Drug Sales Market Share by Country (2017-2028)

Figure 69. South America Pancreatic Endocrine Tumor Drug Revenue Market Share by Country (2017-2028)

Figure 70. Brazil Pancreatic Endocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 71. Argentina Pancreatic Endocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 72. Middle East & Africa Pancreatic Endocrine Tumor Drug Sales Market Share by Type (2017-2028)

Figure 73. Middle East & Africa Pancreatic Endocrine Tumor Drug Sales Market Share by Application (2017-2028)

Figure 74. Middle East & Africa Pancreatic Endocrine Tumor Drug Sales Market Share by Region (2017-2028)

Figure 75. Middle East & Africa Pancreatic Endocrine Tumor Drug Revenue Market Share by Region (2017-2028)

Figure 76. Turkey Pancreatic Endocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 77. Egypt Pancreatic Endocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 78. Saudi Arabia Pancreatic Endocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 79. South Africa Pancreatic Endocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 80. Manufacturing Cost Structure Analysis of Pancreatic Endocrine Tumor Drug in 2021

Figure 81. Manufacturing Process Analysis of Pancreatic Endocrine Tumor Drug

Figure 82. Pancreatic Endocrine Tumor Drug Industrial Chain

Figure 83. Sales Channel: Direct Channel vs Indirect Channel

Figure 84. Methodology

Figure 85. Research Process and Data Source